Keeper Security Extends Agentic AI Governance to Endpoint Privilege Manager

For the first time, AI agents on employee workstations and endpoints can be discovered and governed with access policies and elevation controls Gartner predicts that by 2028, an average global Fortune ...

Scylos Appoints Paul J. Caracciolo to Board of Advisors

Healthcare technology and cybersecurity leader brings two decades of CTO and CISO experience to Scylos as the company ...
CSO Online

Why The Gentlemen ransomware is a test of identity and recovery controls

The ransomware’s use of trusted administrative tools and recovery-disruption tactics shows why containment, not just endpoint ...
Psychiatry Advisor

Intranasal Fasedienol Shows Mixed Results in Social Anxiety Trial

Topline data from the phase 3 PALISADE-4 trial showed that fasedienol nasal spray did not significantly improve acute anxiety compared with a placebo in the overall SAD population.

Tenax Therapeutics: 'Hold' TNX-103 Data August 2026 - But With Caution Ahead

Tenax Therapeutics, Inc. downgraded to Hold ahead of Aug 2026 phase 3 TNX-103 data in PH-HFpEF; weigh 6MWD odds, downside, ...
The American Journal of Managed Care

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...
BizTech Magazine

AMD-Powered AI PCs Help Organizations Prepare for the Next Wave of Copilot

But as organizations gain experience with generative AI, many are discovering that the endpoint itself is becoming an ...

Jamf exec: The exploit isn’t what gives attackers away

Jamf this week unveiled Beacon, a threat-hunting service that aims to provide dedicated, proactive detection and analysis of ...
InfoWorld

Argo CD flaw shows why GitOps infrastructure should be treated as tier zero

The unpatched vulnerability could give attackers a pathway from a compromised pod to broader control over Kubernetes ...

Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial

Can-Fite has reported that its Phase IIa study of Namodenoson in advanced pancreatic ductal adenocarcinoma patients achieved ...
The Barre-Montpelier Times Argus

Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive results from the Phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS ...